$0.43
-0.03 (-5.75%)
Open$0.45
Previous Close$0.46
Day High$0.45
Day Low$0.42
52W High$8.94
52W Low$0.37
Volume—
Avg Volume1.70M
Market Cap18.33M
P/E Ratio—
EPS$-1.71
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,619.8% upside
Current
$0.43
$0.43
Target
$7.44
$7.44
$4.65
$7.44 avg
$8.88
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.30M | 4.98M | 4.38M |
| Net Income | -11,481 | -9,902 | -8,948 |
| Profit Margin | -0.2% | -0.2% | -0.2% |
| EBITDA | -10,930 | -11,209 | -8,630 |
| Free Cash Flow | -9,428 | -11,072 | -6,340 |
| Rev Growth | +3.9% | +11.7% | +7.6% |
| Debt/Equity | 0.42 | 0.41 | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |